SI-BONE, Inc. Provides Preliminary and Unaudited Revenue Guidance for the Fourth Quarter, Full Year of 2019 and Full Year of 2020
January 09, 2020 at 08:09 am
Share
SI-BONE, Inc. provided preliminary and unaudited revenue guidance for the fourth quarter, full year of 2019 and full year of 2020. Preliminary and unaudited revenue for fourth quarter 2019 is expected to be in the range of $19.5 million to $19.8 million, reflecting growth of 25% to 27% compared to the prior year period.
Preliminary and unaudited revenue for full year 2019 is expected to be in the range of $67.0 million to $67.3 million, reflecting growth of approximately 21% over full year 2018.
The company expects full year 2020 revenue to be in the range of $80 million to $82 million, representing growth of approximately 19% to 22% over preliminary and unaudited full year 2019 revenue.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE, INC. 
